FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235		

OMB Number:	3235-028
Estimated averag	je burden
hours per respons	se: 0.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Tarriff Scott					<u>E</u>	2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]								(Che	neck all applicable) X Director		ting Person(s) to Issuer 10% Owner		/ner
(Last)	(F	First)	(Middle)													Officer (give title below)		Other (s below)	pecify
C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315						3. Date of Earliest Transaction (Month/Day/Year) 03/30/2018										<u> </u>	EO		
(Street) WOODO LAKE	CLIFF N	IJ	07677		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc Line)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(5	State)	(Zip)																
		Та	ble I - No	n-Dei	rivativ	ve Se	ecur	ities Ac	quire	ed, Di	sposed o	of, or	Bene	eficially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Cod	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr.				5. Amoun Securities Beneficia Owned Fo Reported	s For ally (D) ollowing (I) (: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Cod	ie V	Amount	(A (I	A) or D)	Price	Transacti	Transaction(s) (Instr. 3 and 4)			(111341. 4)	
Common Stock 03/3				30/201	/2018		M	[113,10)4	A	\$4.04	1,483	3,050		D			
Common Stock 03/30/			30/201	/2018		F		57,895	57,895 ⁽¹⁾ D		\$52.69	1,425,155			D				
			Table II -								posed of converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (8)				6. Date Exercis Expiration Date (Month/Day/Ye		ate	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	0	Amount or Jumber of Shares		Transacti (Instr. 4)	on(s)		
Employee Stock Option (Right to	\$4.04	03/30/2018			M	М		113,104		2)	10/02/2018	10/02/2018 Common Stock 113		113,104	\$0.00	0		D	

Explanation of Responses:

- 1. Represents shares withheld to pay exercise price and to satisfy withholding tax obligations.
- 2. Fully vested.

Remarks:

/s/ Scott Tarriff

** Signature of Reporting Person

04/03/2018 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.